An increasing demand for active lifestyles as patients refuse to be disabled by osteoarthritis is one of the primary drivers of the European osteoarthritis market. Patients are seeking pharmacological treatment options rather than undergo surgical procedures, and this is promoting the demand for osteoarthritis drugs in Europe, where around 35 to 40 million of the population suffer from this disease in varying degrees of severity.
New analysis from Frost & Sullivan (pharmaceuticals.frost.com), European Osteoarthritis Market, reveals that this market earned revenues of $121.2 million in 2006 and estimates this to reach $139.7 million in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of European Osteoarthritis Market, then send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore@[.]frost.com with your full name, company name, title, telephone number, fax number and email address. Upon receipt of the above information, an overview will be sent to you by email.
“It must be kept in mind, however, that there are no actual curative therapies available for osteoarthritis,” notes Frost & Sullivan Industry Analyst Ms. Sylvia Miriyam Findlay. “The focus of osteoarthritis management is rather on reducing pain, inflammation and disability by retarding cartilage damage and increasing joint function.”
Non-steroidal anti-inflammatory drugs (NSAIDs) are the class of medications most commonly used to treat mild to moderate arthritic pain. Traditional NSAIDs are non-selective and act by blocking both cyclooxygenase (COX) 1 and 2 that are involved in prostaglandin production.
However, some of these NSAIDs, even the highest-selling ones, were withdrawn from the market due to significant doubts over their side effects and safety profile. Due to these controversies, the physician and patient community is now looking to newer treatment options such as hyaluronic acid (HA) or steroidal injections for pain relief.
The HA market has been gaining popularity in Europe and is poised to penetrate the European osteoarthritis market further, but this is likely to occur only if sufficient clinical trials substantiate the efficacy of this therapy. The HA market is still untapped and is likely to attract many more participants, while its low entry barriers could encourage the introduction of newer HA products.
Proper diagnosis of the disease is still a major unmet need in the industry, as there are no effective biomarkers or diagnostic tests available to diagnose or monitor the progression of the disease. There also exists a real need for the introduction of disease-modifying drugs with an improved safety profile.
Currently, there is a huge gap in treatment options if patients do not respond to the current pain-relieving therapies and are not ready for joint replacement. These are the critical restraints for the European osteoarthritis market.
“Companies are pursuing stem cell therapies to address this need as these are not only non-invasive but also lead to tissue regeneration,” says Ms. Findlay. “Such therapies are likely to enhance the growth of the European osteoarthritis market.”
European Osteoarthritis Market, part of the Pharmaceutical and Biotechnology Growth Partnership Service programme, provides an overview of the current treatment options along with a complete analysis of key market drivers, restraints and trends prevailing in the market. It also provides a detailed analysis of the hyaluronic acid market, its revenues and technological advancements. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.